<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: O6-methylguanine-DNA-methyltransferase (MGMT) is a DNA repair protein removing mutagenic and cytotoxic adducts from O6-<z:chebi fb="1" ids="16235">guanine</z:chebi> in DNA </plain></SENT>
<SENT sid="1" pm="."><plain>Approximately 40% of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) display MGMT deficiency due to promoter hypermethylation leading to silencing of the gene </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="22333">Alkylating agents</z:chebi>, such as <z:chebi fb="0" ids="4305">dacarbazine</z:chebi>, exert their antitumor activity by DNA methylation at the O6-<z:chebi fb="1" ids="16235">guanine</z:chebi> site, inducing base pair mismatch, therefore activity of <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> could be enhanced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> lacking MGMT </plain></SENT>
<SENT sid="3" pm="."><plain>We conducted a phase II study with <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> who had failed standard therapies (<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, irinotecan, fluoropyrimidines, and cetuximab or panitumumab if KRAS <z:mp ids='MP_0002169'>wild type</z:mp>) </plain></SENT>
<SENT sid="4" pm="."><plain>EXPERIMENTAL DESIGN: <z:hpo ids='HP_0000001'>All</z:hpo> patients had <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue assessed for MGMT as promoter hypermethylation in double-blind for treatment outcome </plain></SENT>
<SENT sid="5" pm="."><plain>Patients received <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> 250 mg/m2 i.v. qd for 4 consecutive days q21 until <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> or intolerable toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>We employed a Simon two-stage design to determinate if the ORR would be â‰¥ 10% </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary endpoints included association of response, PFS and disease control rate with MGMT status </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Sixty-eight patients were enrolled from May 2011 to March 2012 </plain></SENT>
<SENT sid="9" pm="."><plain>Patients received a median of 3 cycles of <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> [range 1-12] </plain></SENT>
<SENT sid="10" pm="."><plain>Grade 3-4 toxicities included: <z:mp ids='MP_0002899'>fatigue</z:mp> (41%), <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> (29%), <z:hpo ids='HP_0002019'>constipation</z:hpo> (25%), platelet count decrease (19%), <z:hpo ids='HP_0001903'>anemia</z:hpo> (18%) </plain></SENT>
<SENT sid="11" pm="."><plain>Overall, 2 patients (3%) achieved partial response (PR) and 8 patients (12%) had stable disease (SD) </plain></SENT>
<SENT sid="12" pm="."><plain>Disease control rate (PR+SD) was significantly associated with MGMT promoter hypermethylation in the corresponding <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Objective clinical responses to <z:chebi fb="0" ids="4305">dacarbazine</z:chebi> in metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients are confined to those <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> harbouring epigenetic inactivation of the DNA repair enzyme MGMT </plain></SENT>
</text></document>